



MC-Rx
Powered by ProCare Rx

In-Focus

September 2020

MC-Rx's P&T Committee and team of dedicated clinicians have recommended the following changes to MC-Rx's National Formulary as of the effective dates shown. These decisions follow their clinical guidance and are based on safety, efficacy, side effect profile, and potential for abuse. While financial impact does not play a key role in the decision of coverage and preliminary placement, the ultimate cost of therapy of the selected products versus that of the other available products in the same therapeutic class is taken into consideration during final placement.

New BRAND Name Drug Additions to the Formulary

Clinical Category	Brand Name Generic Name	Route	Indications	Formulary Placement	Effective Date
Fumaric Acid Derivative	Bafiertam (monomethyl fumarate)	Oral (Specialty)	Indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.	Tier 3 P/A	9/1/20
Anaplerotic Agent	Dojolvi (triheptanoin)	Oral (Specialty)	Indicated for treatment of pediatric and adult patients with molecularly confirmed long-chain fatty acid oxidation disorders (LC-FAOD).	Tier 3 P/A	9/1/20
Nonsteroidal Anti-inflammatory	Elyxyb (celecoxib oral solution)	Oral	Indicated for acute treatment of migraine with or without aura in adults.	Tier 3 P/A	9/1/20
Antineoplastic Agent	Fensolvi (leuprolide acetate)	Subcutaneous (Specialty)	Indicated for pediatric patients 2 years of age or older with central precocious puberty.	Tier 3 P/A	9/1/20
Anticonvulsant	Fintepla (fenfluramine)	Oral	Indicated for treatment of seizures associated with dravet syndrome in patients 2 years of age and older.	Tier 3 P/A	9/1/20
Antiemetic	Gimoti (metoclopramide)	Nasal	Indicated for relief of symptoms in adults with acute and recurrent diabetic gastroparesis.	Tier 3 P/A	9/1/20
Antirheumatic	Hulio (adalimumab-fkjp)	Subcutaneous (Specialty)	Indicated for treatment of RA, JIA, PsA, AS, CD, UC, PS.	Tier 3 P/A	9/1/20
Antineoplastic Agent	Inqovi (decitabine and cedazuridine)	Oral (Specialty)	Indicated for adult patients with myelodysplastic syndrome (MDS).	Tier 2 P/A	9/1/20
Anti-Parkinson Agent	Kynmobi (apomorphine hydrochloride)	Sublingual	Indicated for acute, intermittent treatment of "off" episodes in patients with Parkinson's disease.	Tier 3	9/1/20
Insulin	Lyumjev (insulin lispro-aabc)	Subcutaneous	Indicated to improve glycemic control in adults with diabetes mellitus.	Tier 3	9/1/20
Antidiarrheal	Mycapssa (octreotide)	Oral (Specialty)	Indicated for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide.	Tier 3 P/A	9/1/20
Hematopoietic Agent	Nyvepria (pegfilgrastim-apgf)	Subcutaneous (Specialty)	Indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.	Tier 3 P/A	9/1/20
Estrogen Derivative	Oriahnn (elagolix/estradiol/norethindrone acetate and elagolix)	Oral	Indicated for management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) in premenopausal women.	Tier 2 P/A	9/1/20
Contraceptive	Phexxi Vaginal Gel (lactic acid, citric acid, and potassium bitartrate)	Vaginal	Indicated for the prevention of pregnancy in females of reproductive potential for use as an on-demand method of contraception.	Tier 3	9/1/20
Antineoplastic Agent	Qinlock (ripretinib)	Oral (Specialty)	Indicated for adult patients with advanced GIST who have received prior treatment with 3 or more kinase inhibitors, including imatinib.	Tier 2 P/A	9/1/20

New BRAND Name Drug Additions to the Formulary

Clinical Category	Brand Name Generic Name	Route	Indications	Formulary Placement	Effective Date
Antineoplastic Agent	Retevmo (selpercatinib)	Oral (Specialty)	Indicated for adult patients with metastatic RET fusion-positive NSCLC and medullary thyroid cancer who require systemic therapy and who are radioactive iodine refractory.	Tier 2 P/A	9/1/20
Antiretroviral Agent	Rukobia (fostemsavir)	Oral (Specialty)	Indicated for treatment of HIV-1 infection in heavily treatment-experienced adults with multi-drug-resistant HIV-1 infection failing their current antiretroviral regimen due to resistance intolerance or safety considerations.	Tier 2 P/A	9/1/20
Insulin	Semglee (insulin glargine)	Subcutaneous	Indicated to improve glycemic control in adults and pediatric patients with type 1 DM and in adults with type 2 DM.	Tier 3	9/1/20
Antineoplastic Agent	Tabrecta (capmatinib)	Oral (Specialty)	Indicated for adult patients with metastatic NSCLC whose tumors have mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test.	Tier 2 P/A	9/1/20
Imidazoline Derivative	Upneeq (oxymetazoline hydrochloride)	Ophthalmic	Indicated for treatment of acquired blepharoptosis in adults.	Tier 3	9/1/20
Acne Products	Zilxi (minocycline)	Topical	Inflammatory lesions of rosacea in adults.	Tier 2	9/1/20

Medical Benefit

Clinical Category	Brand Name Generic Name	Route	Indications	Formulary Placement	Effective Date
Antimalarial	Artesunate	Intravenous	Indicated for the treatment of malaria.	Medical Benefit	9/1/20
Benzodiazepine	Byfavo (remimazolam)	Intravenous	Used for procedural sedation.	Medical Benefit	9/1/20
Radiopharmaceutical	Cerianna (fluoroestradio F18)	Intravenous	Indicated for the use of diagnostic investigation.	Medical Benefit	9/1/20
Antineoplastic Agent	Darzalex Faspro (daratumumab and hyaluronidase-fihj)	Intravenous	Indicated for treatment of multiple myeloma.	Medical Benefit	9/1/20
Radiopharmaceutical	Tauvid (flortaucipir F18)	Intravenous	Indicated for the use of diagnostic and investigation.	Medical Benefit	9/1/20

Generic Releases & Updates Within the Next 90 Days

The following drugs are expected to lose their patents and become available generically within the next 90 days.

Proventil HFA	Ultravate Lotion	
Cloderm		
Sklice		
Desonate Gel		
Taclonex Scalp		
Noxafil Oral Suspension		
Vascepa		

Additional Notes

Copies of MC-Rx's National Formulary and Pocket Formulary can be found on our website, <http://www.mc-rx.com>, under the "PBM Resources/Drug and Formulary Lists" tab.